Moleculin Biotech Inc (MBRX) — Cash Flow-to-Debt Ratio
Moleculin Biotech Inc (MBRX) has a Cash Flow-to-Debt Ratio of -0.75x as of December 2025, meaning its operating cash flow of $-5.37 Million could theoretically repay -1% of its total liabilities ($7.12 Million) in one year. See working capital to net assets of Moleculin Biotech Inc to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Moleculin Biotech Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Moleculin Biotech Inc across 11 annual periods. Also explore MBRX net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Moleculin Biotech Inc (2015–2025)
Year-by-year debt coverage analysis for Moleculin Biotech Inc. For market capitalisation and broader financial context, see market cap of Moleculin Biotech Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.19x | $-22.73 Million | $7.12 Million | ▼ -46.5% |
| 2024 | -2.18x | $-23.86 Million | $10.95 Million | ▼ -9.8% |
| 2023 | -1.98x | $-24.10 Million | $12.14 Million | ▲ +62.4% |
| 2022 | -5.28x | $-27.64 Million | $5.23 Million | ▼ -42.1% |
| 2021 | -3.72x | $-18.95 Million | $5.10 Million | ▼ -135.8% |
| 2020 | -1.58x | $-17.77 Million | $11.27 Million | ▲ +11.4% |
| 2019 | -1.78x | $-17.20 Million | $9.66 Million | ▲ +22.5% |
| 2018 | -2.30x | $-12.20 Million | $5.31 Million | ▲ +25.8% |
| 2017 | -3.10x | $-7.32 Million | $2.37 Million | ▼ -17.8% |
| 2016 | -2.63x | $-3.76 Million | $1.43 Million | ▼ -379.6% |
| 2015 | -0.55x | $-423.51K | $772.79K | — |